Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company reported a narrowing decline in revenue, with improved profitability driven by cost control measures [5][7] - The second quarter showed a significant recovery in net profit, with a year-on-year increase of 71% [4][5] - The company is focusing on optimizing its resource allocation and enhancing its operational efficiency [5][6] Financial Performance Summary - For the first half of 2025, total revenue was 3.532 billion yuan, a decrease of 23% year-on-year, while net profit attributable to shareholders was 737 million yuan, down 17% [4] - In Q2 2025, total revenue was 1.741 billion yuan, a decrease of 12% year-on-year, but net profit increased by 71% [4] - The gross margin for H1 2025 was 68.55%, with a slight decrease of 0.01 percentage points, while Q2 2025 saw an increase of 2 percentage points to 68.43% [5] - The company reduced its sales expense ratio by 5 percentage points in H1 and 11 percentage points in Q2, indicating effective cost control [5] Revenue and Profit Forecast - The company expects a further narrowing of revenue decline and an increase in profit margins for the full year 2025 [7] - The adjusted earnings per share (EPS) forecasts for 2025-2027 are 0.46, 0.52, and 0.60 yuan respectively, with corresponding price-to-earnings (PE) ratios of 27, 24, and 21 times [7][10]

证券代码：603102 证券简称：百合股份 公告编号：2025-030 威海百合生物技术股份有限公司 关于首次公开发行部分限售股上市流通的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： ? 本次股票上市类型为 首发 股份；股票认购方式为 网下 ，上市股数为 本次股票上市流通总数为28,135,545股。 ? 本次股票上市流通日期为2025 年 8 月 15 日。 一、本次限售股上市类型 威海百合生物技术股份有限公司（以下简称"公司"）经中国证券监督管理 委员会（以下简称"中国证监会"）《关于核准威海百合生物技术股份有限公司 首次公开发行股票的批复》（证监许可〔2022〕36 号）核准，向社会公开发行人 民币普通股（A 股）16,000,000 股，并于 2022 年 1 月 25 日在上海证券交易所主板 上市。 公司首次公 开发行前总股本为 48,000,000 股，首次公 开发行后总股本为 股，占公司总股本的 43.96%，共涉及 2 名股东，限售股锁定期为自公司股票上市 之日起 36 个月，由于公 ...

格隆汇8月11日｜国盛证券研报指出，汤臣倍健优化销售费用投放，盈利能力大幅改善。25Q2公司营收 降幅缩窄，除基数走低外，一方面受益于公司强化用户运营、提升销售转化，另一方面受益于公司加速 推新，线上推出高价格带产品，线下完善大众价格带布局。展望下半年，24H2公司收入端在消费力承 压、大单品新老品替换去库存、行业竞争加剧等影响下形成极低基数，25Q2-Q3公司新品陆续上市，并 将针对性匹配营销资源投入，预计25H2在极低基数、新品支撑下收入增速或迎转正，其中主品牌和 LSG仍有望成为拉动营收增长的主要驱动。利润端来看，公司将持续完善电商投放策略，加大对核心品 类升级品的投资，在抖音等兴趣电商或增加自播投入尝试，费投有望持续优化，贡献利润弹性，盈利能 力有望持续向好。 ...

国盛证券研报指出，汤臣倍健优化销售费用投放，盈利能力大幅改善。25Q2公司营收降幅缩窄，除基 数走低外，一方面受益于公司强化用户运营、提升销售转化，另一方面受益于公司加速推新，线上推出 高价格带产品，线下完善大众价格带布局。展望下半年，24H2公司收入端在消费力承压、大单品新老 品替换去库存、行业竞争加剧等影响下形成极低基数，25Q2-Q3公司新品陆续上市，并将针对性匹配营 销资源投入，预计25H2在极低基数、新品支撑下收入增速或迎转正，其中主品牌和LSG仍有望成为拉 动营收增长的主要驱动。利润端来看，公司将持续完善电商投放策略，加大对核心品类升级品的投资， 在抖音等兴趣电商或增加自播投入尝试，费投有望持续优化，贡献利润弹性，盈利能力有望持续向好。 ...

Summary of the Conference Call for汤臣倍健 Company Overview - **Company**:汤臣倍健 - **Industry**: Health Supplements Key Points and Arguments Financial Performance - In Q2 2025, the company reported a non-GAAP net profit growth of 133% year-on-year, indicating a significant recovery in profitability. However, the overall net profit for the first half of the year declined by 17.3% year-on-year [2][3] - Revenue for the first half of 2025 was 3.5 billion yuan, a year-on-year decrease of 23.4%. The decline in revenue narrowed to 11.5% in Q2 [3] - The company expects a single-digit decline in annual revenue, with the specific extent depending on Q3 performance [2][4] Product and Marketing Strategy - The company has been actively reforming its product, operations, and marketing strategies, achieving the highest product launch frequency in history during Q2 [2][3] - There is a focus on differentiating products between online and offline channels, with offline efforts centered on basic nutritional products and online on high-priced innovative products [2][3] - The main brand and Life Space Group (LSG) are expected to drive revenue growth in the second half of the year, with LSG showing particularly strong performance [7][8] Gross Margin and Cost Management - The gross margin for the first half of 2025 remained stable compared to the previous year, with a notable increase of 1.6 percentage points in Q2. Online gross margin improved significantly due to higher sales of high-margin products on platforms like JD.com [5][21] - The company has managed to control inventory and accounts receivable risks effectively, with proactive measures in place to mitigate potential issues [17] Brand Performance and Challenges - The健力多 brand faces uncertainties due to changes in leadership, new regulatory approvals, and product matrix optimization. Its online performance is better than offline, but conversion rates need continuous improvement [6][9] - The number of distributors decreased by approximately 140 in the first half of the year due to business adjustments and underperformance of new ventures [9] Market Trends and Competitive Landscape - The online sales environment remains competitive, with only JD.com showing growth among major platforms. Future efforts will focus on all key platforms, especially Douyin [13][24] - The company anticipates that online sales will outperform offline sales in the second half of the year, as online channels represent a growth market [15] New Product Development - New products such as盖 DK and high-concentration fish oil have performed well, contributing positively to sales and attracting new customers [18][26] - The company plans to continue optimizing new product promotions and expand production lines to meet diverse market demands [19] Future Outlook - The company aims for a revenue growth target of approximately 50% in the second half of the year, driven by marketing activities and new product launches [29] - Overall, the company expects net profit margins to improve slightly compared to the previous year, with management expenses remaining stable [32] Risks and Considerations - The rising price of whey protein (up 50% year-on-year) has limited impact on overall gross margins due to proactive supplier management [21] - The rapid growth of live-streaming e-commerce presents both opportunities and regulatory challenges, necessitating ongoing operational optimization [27] Additional Important Information - The company is focusing on the oral beauty segment targeted at young women, despite some underperformance in specific brands due to strategic choices [20] - The overall inventory situation among distributors has remained stable, with no significant trends in inventory reduction or accumulation [28]

Core Insights - The company reported a decline in revenue and net profit for the first half of 2025, with a revenue of 3.532 billion yuan, down 23.43% year-on-year, and a net profit of 737 million yuan, down 17.34% year-on-year [1] - However, the second quarter of 2025 showed signs of recovery, with revenue of 1.741 billion yuan, a decrease of only 11.51% year-on-year, and a significant increase in net profit by 71.44% year-on-year [1][2] Revenue Performance - The overall revenue performance in the first half of 2025 was under pressure, but the decline in the second quarter was significantly narrowed compared to the first quarter [2] - In Q1 2025, the company achieved revenue of 1.792 billion yuan, down 32.29% year-on-year, while Q2 revenue was 1.741 billion yuan, down 11.51% year-on-year [2] - The main brand "汤臣倍健" generated revenue of 905 million yuan in Q2, down 17.0% year-on-year, while the international brand LSG saw a revenue increase of 12.4% year-on-year [2] Profitability and Cost Management - The gross margin improved in Q2 2025, with a gross margin of 68.43%, up 1.68 percentage points year-on-year [3] - The company significantly reduced its sales expense ratio in Q2 2025 to 39.65%, down 10.99 percentage points year-on-year, by optimizing its expense allocation and reducing advertising spending [3] - Advertising expenses for the first half of 2025 were 243 million yuan, down 53.49% year-on-year, contributing to the improved profitability [3] Business Development - The company made progress in its international and infant nutrition segments, expanding its presence in Southeast Asia and enhancing its brand "天然博士" for infant nutrition [4] - The company is focusing on brand upgrades and increasing its market influence while launching new products to create additional growth opportunities [4] Future Outlook - The company aims to enhance operational quality and optimize sales strategies in the second half of 2025, with new products expected to contribute positively to revenue [4] - Projections for net profit from 2025 to 2027 are 784 million yuan, 889 million yuan, and 1 billion yuan, representing year-on-year growth of 20%, 14%, and 12% respectively [4]

Core Insights - The core of health product sales lies in acquiring accurate customer data for targeted marketing [1][2] - Traditional marketing methods are losing effectiveness due to strict regulations and efforts to combat fraud against the elderly [1][2] - Some companies are innovating by collaborating with social organizations and hospitals to host large health events to gather customer information [1][5] Group 1: Marketing Strategies - Companies are organizing health activities under the guise of social organizations to enhance credibility and attract participation [2][5] - These activities often involve collecting personal health data under the pretext of scientific research, which raises concerns about their true intentions [5][14] - The use of awards and recognition during these events encourages ongoing participation and data collection, creating a cycle of engagement [9][10] Group 2: Regulatory Environment - The national regulatory body is actively working to protect the elderly from fraudulent health product marketing practices [1][2] - The rise of these new marketing strategies poses challenges for regulators, as they often operate within legal boundaries while still being exploitative [10][14] - Companies that rely on traditional marketing methods face greater risks of regulatory scrutiny compared to those employing these innovative strategies [10][14] Group 3: Consumer Behavior - Consumers are often misled into believing that their participation in these activities contributes to public health, while it primarily serves corporate interests [14] - The emotional appeal and perceived authority of these events can lead consumers to willingly provide personal data and make high-priced purchases [13][14] - There is a need for consumers to remain cautious and rational, especially regarding the sharing of personal health information [14]

Core Viewpoint - The recent financial report of Tongchen Beijian (300146) indicates a decline in revenue and net profit for the first half of 2025, with significant changes in various financial metrics compared to the previous year [1] Financial Performance - Total revenue for the first half of 2025 was 3.532 billion yuan, a decrease of 23.43% year-on-year [1] - Net profit attributable to shareholders was 737 million yuan, down 17.34% year-on-year [1] - In Q2 2025, total revenue was 1.741 billion yuan, a decline of 11.51% year-on-year, while net profit for the quarter increased by 71.44% to 282 million yuan [1] - Gross margin stood at 68.55%, a slight decrease of 0.01% year-on-year, while net margin increased by 13.29% to 21.61% [1] - Total operating expenses were 1.448 billion yuan, accounting for 40.98% of revenue, a decrease of 7.78% year-on-year [1] - Earnings per share (EPS) was 0.43 yuan, down 17.31% year-on-year, while operating cash flow per share increased by 118.12% to 0.38 yuan [1] Accounts Receivable and Liabilities - Accounts receivable amounted to 504 million yuan, representing 77.24% of the latest annual net profit [1] - Interest-bearing liabilities surged by 6320.54% to 84.3 million yuan [1] Market and Business Model - The company's return on invested capital (ROIC) was 4.81% last year, indicating weak capital returns, with a historical median ROIC of 14% over the past decade [1] - The business model relies heavily on marketing-driven performance, necessitating further investigation into the underlying drivers of this approach [1] Analyst Expectations - Analysts project a net profit of 781 million yuan for 2025, with an average EPS estimate of 0.46 yuan [2] Fund Holdings - The largest fund holding Tongchen Beijian is the Manulife Consumer Dividend Index A, with 2.1437 million shares and a total size of 576 million yuan [3][4] - The fund has seen a 12.47% increase in value over the past year [4] Southeast Asia Market Focus - The company is currently focusing on the Southeast Asian market, particularly Indonesia, where it is in the process of obtaining market access [5]

Group 1 - The core viewpoint of the news is that Tongchen Beijian (300146.SZ) reported its semi-annual results for 2025, revealing a total of 1.07 billion shares held by institutional investors, accounting for 6.27% of the company's total equity [1] - As of August 8, 2025, there are 9 institutional investors holding shares in Tongchen Beijian, with a slight decrease of 0.09 percentage points in institutional holding compared to the previous quarter [1] - The institutional investors include various funds such as E Fund's ChiNext ETF and Hong Kong Central Clearing Limited, indicating a diverse investment base [1] Group 2 - In the public fund sector, 4 funds increased their holdings, with a total increase of 0.12% compared to the previous period [2] - One public fund, E Fund's ChiNext ETF, reported a slight decrease in holdings, while one fund, Huatai-PineBridge's major consumption ETF, did not disclose holdings this period [2] - Foreign investment sentiment showed a decrease in holdings from Hong Kong Central Clearing Limited, with a reduction of 0.13% compared to the previous quarter [2]

Core Viewpoint - The company reported a revenue of 3.532 billion yuan and a net profit of 737 million yuan for the first half of 2025, driven by innovative products and operational improvements [1] Group 1: Financial Performance - The company achieved a revenue of 3.532 billion yuan and a net profit of 737 million yuan during the reporting period [1] - The performance reflects the impact of innovative product offerings and enhanced operational efficiency [1] Group 2: Product Strategy - The company focused on basic nutrient categories that are widely consumed and frequently purchased, aiming to provide high cost-performance products [1] - New products such as protein powder, calcium DK, glucosamine, and probiotics have contributed to a rebound in market share [1] - The calcium DK product, in particular, showed significant customer acquisition effects during initial trials [1] Group 3: Market Positioning - The company's main brand products, including premium protein powder and liquid calcium, performed well, ranking in the top 10 of new products on Tmall during the "618" shopping festival [1] - Data from JD platform indicates a breakthrough in product features, enhancing competitive positioning [1] Group 4: Research and Development - The company is advancing the application of research outcomes in product development, focusing on areas such as anti-aging and precision nutrition [1] - A study on natural anti-aging conducted in collaboration with institutions was published in the international journal "Aging Cell" [1] Group 5: International Expansion - The company is accelerating its overseas market expansion and actively exploring new growth opportunities abroad [1]